VolitionRx (NYSE:VNRX) Coverage Initiated at HC Wainwright

HC Wainwright initiated coverage on shares of VolitionRx (NYSE:VNRX) in a research report released on Tuesday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $2.50 price objective on the stock.

VNRX has been the subject of a number of other research reports. StockNews.com started coverage on VolitionRx in a report on Saturday. They issued a “sell” rating for the company. D. Boral Capital restated a “buy” rating and set a $5.00 price target on shares of VolitionRx in a report on Monday, March 31st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $3.33.

VolitionRx Stock Performance

Shares of NYSE:VNRX opened at $0.46 on Tuesday. VolitionRx has a 52-week low of $0.42 and a 52-week high of $1.02. The company has a market capitalization of $44.41 million, a PE ratio of -1.28 and a beta of 1.15. The company has a fifty day moving average of $0.57 and a 200-day moving average of $0.63.

Insider Buying and Selling

In other news, CEO Cameron John Reynolds purchased 181,818 shares of the stock in a transaction on Wednesday, March 26th. The stock was purchased at an average price of $0.55 per share, for a total transaction of $99,999.90. Following the acquisition, the chief executive officer now owns 2,299,222 shares in the company, valued at $1,264,572.10. This trade represents a 8.59 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 12.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On VolitionRx

Several large investors have recently modified their holdings of VNRX. Geode Capital Management LLC grew its stake in VolitionRx by 15.1% during the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after purchasing an additional 95,900 shares during the period. Two Sigma Securities LLC bought a new position in shares of VolitionRx during the 4th quarter worth approximately $29,000. Northern Trust Corp grew its position in shares of VolitionRx by 32.0% during the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after buying an additional 28,579 shares during the period. Lagoda Investment Management L.P. increased its stake in shares of VolitionRx by 24.3% in the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after acquiring an additional 1,481,000 shares in the last quarter. Finally, Millennium Management LLC bought a new stake in shares of VolitionRx in the 4th quarter valued at $36,000. 8.09% of the stock is currently owned by institutional investors and hedge funds.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.